LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company, announced that its stockholders have approved the merger with Alumis Inc. (Nasdaq: ALMS). At a special meeting held today, ACELYRIN stockholders voted in favor of the merger agreement, which stipulates that they will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. The merger aims to create a biopharma company dedicated to developing and commercializing transformative therapies for immune-mediated diseases. The transaction is expected to be completed in the second quarter of 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。